We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. One of the best biotech stocks on our list is Altimmune, Inc. TheFly reported on January 27 that Barclays initiated coverage of ALT with an Overweight rating and a $20 price target. Strong underlying fundamentals, continuous merger and acquisition activity, and alleviating medication pricing concerns are the reasons behind the firm’s optimistic outlook for the biotech industry in 2026. Additionally, Barclays pointed out that A ...

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" to maximize returns in a shorter time frame [1] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point for fast-moving stocks, which can lose momentum if future growth does not justify high valuations [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify promising candidates [3] Group 2: SSAAY Stock Analysis - SSAAY has shown a four-week price change of 8.3%, indicating growing investor interest and positioning it well within the momentum investing framework [4] - Over the past 12 weeks, SSAAY has gained 30.8%, with a beta of 1.35, suggesting it moves 35% more than the market in either direction [5] - SSAAY has a Momentum Score of B, indicating a favorable time to invest based on its momentum characteristics [6] Group 3: Earnings Estimates and Valuation - SSAAY has received upward revisions in earnings estimates, earning a Zacks Rank 2 (Buy), which is associated with strong momentum effects as analysts raise their estimates [7] - The stock is currently trading at a Price-to-Sales ratio of 0.86, suggesting it is undervalued, as investors pay only 86 cents for each dollar of sales [7] Group 4: Additional Investment Opportunities - Besides SSAAY, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting additional investment opportunities [8] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [9]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing - Momentum investors often face challenges in determining the right entry point, as stocks may lose momentum when their valuations exceed future growth potential [2] - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify such opportunities [3] Group 2: Algoma Steel Group Inc. (ASTL) - Algoma Steel Group Inc. (ASTL) has shown a price increase of 6.6% over the past four weeks, indicating growing investor interest [4] - The stock has gained 8.3% over the past 12 weeks, with a beta of 1.56, suggesting it moves 56% higher than the market [5] - ASTL has a Momentum Score of B, indicating a favorable time to invest based on momentum [6] - The stock has a Zacks Rank 1 (Strong Buy) due to upward revisions in earnings estimates, which attract more investors [7] - ASTL is trading at a Price-to-Sales ratio of 0.28, meaning investors pay only 28 cents for each dollar of sales, indicating a reasonable valuation [7] Group 3: Additional Investment Opportunities - Besides ASTL, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, suggesting further investment opportunities [8] - The Zacks Premium Screens offer over 45 different strategies tailored to help investors find winning stock picks [9]

Core Insights - Columbia Financial (CLBK) reported quarterly earnings of $0.15 per share, matching the Zacks Consensus Estimate and showing an increase from $0.11 per share a year ago, resulting in an earnings surprise of +3.45% [1] - The company achieved revenues of $68.78 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 1.37% and up from $57.31 million year-over-year [2] Earnings Performance - Over the last four quarters, Columbia Financial has surpassed consensus EPS estimates three times [2] - The company delivered an earnings surprise of +15.38% in the previous quarter, where it was expected to post earnings of $0.13 per share but achieved $0.15 [1] Stock Performance - Columbia Financial shares have increased approximately 4.7% since the beginning of the year, outperforming the S&P 500's gain of 1.4% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $68.65 million, and for the current fiscal year, it is $0.64 on revenues of $285.85 million [7] - The estimate revisions trend for Columbia Financial was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Financial - Miscellaneous Services industry, to which Columbia Financial belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Group 1 - Momentum investing is characterized by the strategy of "buying high and selling higher," contrasting with the traditional "buy low and sell high" approach [1] - Identifying the right entry point for momentum stocks can be challenging, as they may lose momentum if their valuations exceed future growth potential [1] - ZIM Integrated Shipping Services (ZIM) has shown recent price momentum with a four-week price change of 0.6%, indicating growing investor interest [3] Group 2 - ZIM has gained 49.6% over the past 12 weeks, demonstrating its ability to deliver positive returns over a longer time frame [4] - The stock has a beta of 1.7, suggesting it moves 70% higher than the market in either direction, indicating fast-paced momentum [4] - ZIM holds a Momentum Score of B, suggesting it is an opportune time to invest in the stock [5] Group 3 - ZIM has a Zacks Rank 2 (Buy) due to an upward trend in earnings estimate revisions, which typically attracts more investors [6] - The stock is trading at a Price-to-Sales ratio of 0.35, indicating it is reasonably valued at 35 cents for each dollar of sales [6] - ZIM appears to have significant potential for further price appreciation while maintaining a favorable valuation [7]

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. ImmunityBio, Inc. is among the best biotech stocks. TheFly reported on January 20 that Piper Sandler raised its price target on IBRX to $7 from $5 and maintained an Overweight rating. According to the update, U.S. ANKTIVA net sales increased by almost 700% year over year to $113 million in 2025. Revenue is expected to reach $180 million in 2026. A possible label expansion for ANKTIVA in 2027 may be supported by positive QUILT- ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The seventeenth stock on our list is Arcturus Therapeutics Holdings Inc. TheFly reported on January 22 that Roth Capital initiated coverage of ARCT with a Buy rating and a $20 price target. The firm noted that the company’s two mid-stage programs show clinical activity and have peak sales potential that exceed $1 billion. Roth also highlighted that ARCT shares are trading close to their cash value, effectively pricing in a 0% ...

Group 1 - The Dow Jones industrial average and other major indexes experienced a slight decline on Monday morning [1] - Walt Disney (DIS) saw a drop in stock price due to earnings results, while Palantir Technologies (PLTR) increased ahead of its quarterly results [1] - Oracle (ORCL) stock rose significantly following the announcement of plans to raise up to $50 billion for AI initiatives [1] Group 2 - Tesla (TSLA) stock fell amid discussions surrounding SpaceX and xAI, alongside analysts cutting earnings expectations due to Elon Musk's substantial capital spending plans for 2026 [1] - The overall stock market is mixed, with various companies like Meta, Microsoft, and Amazon leading in earnings reports [1] - Analysts are closely monitoring AI stocks and their performance in the current market environment [1]

Advance Auto Parts (NYSE:AAP) is one of the best Auto Parts stocks according to Hedge Funds. On January 21, Aaron Reed from Northcoast Research indicated his optimism around Advance Auto Parts (NYSE:AAP). He upgraded his rating on the stock from Neutral to Buy, and estimated a price target of $55, which yields an upside of over 14%. Reed’s rating is based on his expectations of strong demand trends during 2026, following the ongoing performance enhancements. Copyright: urfingus / 123RF Stock Photo On t ...

Group 1 - Autoliv Inc (NYSE:ALV) is recognized as one of the best auto parts stocks by hedge funds, with analysts providing mixed ratings and price target adjustments [1][3]. - Baird analyst Luke Junk reaffirmed a Neutral rating for Autoliv, raising the price target from $133 to $137, reflecting a cautious outlook amid supply chain disruptions affecting auto affordability [1][2]. - Wolfe Research's Emmanuel Rosner maintained an Outperform rating but lowered the price target from $149 to $143, indicating a potential upside of over 13% from the current level despite the revision [3]. Group 2 - Rosner anticipates that Autoliv's management may provide 2026 guidance that could exceed Wall Street consensus, projecting adjusted operating margins of approximately 11%, compared to the consensus estimate of 10.8% [4]. - Autoliv is the largest global supplier of automotive safety systems, offering products such as airbags, seatbelts, and pedestrian protection solutions, primarily serving car manufacturers [5].